{"slideshow_credits": null, "snippet": "Baxter International said that the immunoglobulin therapy did not significantly arrest the decline in either cognition or daily functioning when compared with a placebo.", "abstract": "Baxter International says that its drug Gammagard failed clinical trials, another setback for treatment of Alzheimer's disease; late-stage trial did not halt mental decline caused by Alzheimer's, despite anecdotal evidence that gave researchers hope.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/05/08/business/baxter-says-its-new-alzheimers-treatment-has-failed.html", "lead_paragraph": "Baxter International said that the immunoglobulin therapy did not significantly arrest the decline in either cognition or daily functioning when compared with a placebo.", "headline": {"seo": "Alzheimer&#8217;s Treatment Failed Trial, Maker Says", "main": "Alzheimer&#8217;s Treatment Failed Trial, Maker Says ", "print_headline": "Alzheimer\u2019s Treatment Failed Trial, Maker Says"}, "_id": "518920adcf28d05efe0013e5", "word_count": "560", "multimedia": [], "pub_date": "2013-05-08T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Baxter International", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Alzheimer's Disease", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}